Avaliação do efeito analgésico da pregabalina para artralgia após chikungunya. Estudo comparativo duplo-encoberto
Arquivos
Data
2023-06-26
Autores
Rodrigues, Rodrigo Souza 
Orientadores
Rioko, Kimiko Sakata
Tipo
Dissertação de mestrado
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Justificativa e Objetivos: A Chikungunya (chiku) é uma síndrome febril e debilitante associada à artralgia persistente, com redução da produtividade e da qualidade de vida. É caracterizada por duas fases: aguda e crônica. A fase aguda é de curta duração e de sintomas inespecíficos; a fase crônica é marcada pela dor persistente. A dor articular é a principal manifestação clínica em diferentes estágios da doença, causando incapacidade física, com impactos econômicos significativos. Não existem tratamentos específicos para a infecção por chiku. O objetivo primário deste estudo é avaliar o efeito da pregabalina na redução da intensidade da dor da chiku. Os objetivos secundários são avaliar a necessidade de complementação analgésica e a melhora na qualidade de vida. Métodos: O estudo foi prospectivo, longitudinal e analítico. Foram estudados 35 pacientes maiores de 18 anos com dor por mais de 3 meses e intensidade ≥4. Os pacientes foram sorteados e alocados em um dos dois grupos. Um grupo (PH= pregabalina + hidroxicloroquina) recebeu associação da pregabalina (75mg, 1 comprimido ao dia durante 5 dias, e posteriormente 1 comprimido de12h/12h, durante 3 meses) com hidroxicloroquina (400mg, 1 comprimido ao dia durante 3 meses). Outro grupo (H= hidroxicloroquina) recebeu hidroxicloroquina (400mg, 1 comprimido ao dia durante 3 meses). Resultados: Não houve diferença estatística significante na intensidade da dor entre os grupos PH e H, nos tempos avaliados. Não houve diferença significante entre os grupos na complementação analgésica entre os grupos PH e H. Não houve diferença significante entre os grupos na qualidade de vida dos participantes os grupos PH e H. Não houve diferença significante entre os grupos na incidência de efeitos adversos dos participantes.Conclusões: A pregabalina na dose de 75mg/12h, em associação com a hidroxicloroquina, na dose de 400mg/d durante 3 m, não promoveu redução da intensidade da dor e do uso de analgésicos complementares, da melhora na qualidade de vida e também não causou aumento da incidência de efeitos adversos em pacientes com dor articular por chiku.
Background and Objectives: Chikungunya (chiku) is a febrile and debilitating syndrome associated with persistent arthralgia, with reduced productivity and quality of life. It has two phases: acute and chronic. The acute phase is brief and has nonspecific symptoms; the chronic phase is marked by persistent pain. Joint pain is the main clinical manifestation at different stages of the disease, causing physical disability with significant economic impacts. No specific treatments for chiku infection are available. The primary objective of this study was to compare the intensity of pain while on pregabalin combined with hydroxychloroquine vs. hydroxychloroquine alone in patients with arthralgia from chiku. The secondary objective was to compare their need for complementary analgesics and their quality of life. Methods The study was prospective, longitudinal, and analytical. Thirty-five patients older than 18 years with pain for more than 3 months and intensity ≥ 4 were studied. Participants were randomly allocated to one of the two groups. One group received an association of hydroxychloroquine (400 mg, 1 tablet/day for 3 mo.) with pregabalin (75 mg, 1 tablet a day for 5 days, and then 1 tablet 12/12h for 3 months.). The other received hydroxychloroquine (400 mg, 1 tablet a day for 3 months). Results: There was no difference between the groups in the intensity of pain, in the consumption of complementary analgesics, in the quality of life, or in the incidence of adverse effects. Conclusions: Pregabalin combined with hydroxychloroquine did not reduce the intensity of pain or the use of complementary analgesics, improve the quality of life, or cause an increase in the incidence of adverse effects in patients with joint pain due to chiku.
Background and Objectives: Chikungunya (chiku) is a febrile and debilitating syndrome associated with persistent arthralgia, with reduced productivity and quality of life. It has two phases: acute and chronic. The acute phase is brief and has nonspecific symptoms; the chronic phase is marked by persistent pain. Joint pain is the main clinical manifestation at different stages of the disease, causing physical disability with significant economic impacts. No specific treatments for chiku infection are available. The primary objective of this study was to compare the intensity of pain while on pregabalin combined with hydroxychloroquine vs. hydroxychloroquine alone in patients with arthralgia from chiku. The secondary objective was to compare their need for complementary analgesics and their quality of life. Methods The study was prospective, longitudinal, and analytical. Thirty-five patients older than 18 years with pain for more than 3 months and intensity ≥ 4 were studied. Participants were randomly allocated to one of the two groups. One group received an association of hydroxychloroquine (400 mg, 1 tablet/day for 3 mo.) with pregabalin (75 mg, 1 tablet a day for 5 days, and then 1 tablet 12/12h for 3 months.). The other received hydroxychloroquine (400 mg, 1 tablet a day for 3 months). Results: There was no difference between the groups in the intensity of pain, in the consumption of complementary analgesics, in the quality of life, or in the incidence of adverse effects. Conclusions: Pregabalin combined with hydroxychloroquine did not reduce the intensity of pain or the use of complementary analgesics, improve the quality of life, or cause an increase in the incidence of adverse effects in patients with joint pain due to chiku.